Oncology Live®
Vol. 25 No. 7
Volume: 25
Issue: 7
Vol. 25 No. 6
Volume: 25
Issue: 6
Vol. 25 No. 5
Volume: 25
Issue: 5
Vol. 25 No. 4
Volume: 25
Issue: 4
Vol 25/No. 3
Volume: 25
Issue: 3
Vol. 25 No. 2
Volume: 25
Issue: 2
Vol. 25/No. 1
Volume: 25
Issue: 1
Vol. 24/No. 20
Volume: 24
Issue: 20
Vol. 24/No. 18
Volume: 24
Vol. 24/No. 19
Volume: 24
Issue: 19
Vol. 24/No. 17
Volume: 24
Issue: 17
Vol. 24/No. 16
Volume: 24
Issue: 16
Vol. 24/No. 15
Volume: 24
Issue: 15
Vol. 24/No. 14
Volume: 24
Issue: 14
Vol. 24/No. 12
Volume: 24
Vol. 24/No. 13
Volume: 24
Issue: 13
Vol.24/No.11
Volume: 24
Issue: 11
Vol. 24/ No. 10
Volume: 24
Issue: 10
Vol. 24/No. 9
Volume: 24
Issue: 9
Vol. 24/No. 8
Volume: 24
Vol.24/No.7
Vol. 24/No. 5
Volume: 24
Vol. 24/No. 6
Volume: 24
Issue: 6
Vol. 24/No. 4
Volume: 24
Vol. 24/No. 3
Volume: 24
Vol. 24/No. 2
Volume: 24
Issue: 2
Vol. 24/No. 1
Volume: 24
Issue: 1
Vol. 23/No. 23
Volume: 23
Vol. 23/No. 24
Volume: 23
Issue: 24
Vol. 23/No. 21
Volume: 23
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5